« Return to News | Awards & Advancement

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

Griffin, a board-certified physician in both internal medicine and gastroenterology, comes to ImmusanT from his most recent position as head of external innovation for Sanofi's immuno-inflammation therapeutic strategy unit. He has also held positions of increasing responsibility in clinical development at Forest Laboratories.

A former faculty member of Columbia College of Physicians and Surgeons, Griffin also held a private practice in internal medicine and gastroenterology in New York City before he moved to industry. He is also a fellow of the American College of Physicians.

"Patrick brings to ImmusanT exceptional expertise as a gastroenterologist, drug developer and evaluator of numerous drug candidates for immune and inflammatory diseases,” said Leslie Williams, president and CEO, ImmusanT.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.